Paolo Paoletti joins PsiOxus Therapeutics at Chairman

Former President of GSK Oncology adds depth of knowledge of cancer R&D

PsiOxus Therapeutics, a UK-based immuno-oncology company that develops novel therapeutics for serious diseases with a particular focus on cancer, has appointed Paolo Paoletti as Chairman of the Board.

Paoletti was most recently President of GlaxoSmithKline (GSK) Oncology. In this role, he was responsible for R&D, commercial strategy and lifecycle management. Prior to joining GSK, he was Vice President, Clinical Development for Lilly Oncology.

In addition to his role at PsiOxus, Paoletti is also a member of the boards of Genmab, Forma Therapeutics and Nucana BioMed, as well as being the CEO of Kesios Therapeutics.

You may also like

Research & Development

PsiOxus and Bristol-Myers Squibb collaborate on combination clinical immuno-oncology study

The clinical collaboration will support Phase I studies
Research & Development

PsiOxus wins US$3.3m DTRA contract to develop biodefence vaccine adjuvants

Using its proprietary PolyMAP technology to increase antigenic response
Research & Development

PsiOxus closes £22m equity funding round

Will enable firm to advance the clinical development of ColoAd1 oncolytic vaccine
Research & Development

Expanding PsiOxus moves into new facilities

To allow further development of novel cancer drugs and products for clinically unmet diseases
Research & Development

New biotechnology firm is born

PsiOxus Therapeutics will focus on developing novel treatments for cancer and wasting diseases
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Subscribe now